François Ravenelle, Inversago CEO

Up­start sets off on a clin­i­cal jour­ney, look­ing to make a name for its 2nd-gen CB1 block­ers

A small Mon­tre­al-based biotech out to make a name for it­self as a sec­ond-gen de­vel­op­er of CB1 re­cep­tor block­ers has suc­cess­ful­ly gath­ered $35 mil­lion for the next stage of the de­vel­op­ment odyssey it’s on.

The mon­ey, which comes from a high-pro­file group of transat­lantic in­vestors, will be used to pay for the first clin­i­cal for­ays of In­ver­sa­go’s lead drug. And the biotech has a long list of high-pro­file tar­gets in mind, start­ing with Prad­er-Willi syn­drome and run­ning through NASH, type 1 di­a­betes and di­a­bet­ic nephropa­thy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.